[1] Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies[J]. Blood, 2008,111(5):2516-2520. [2] Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: A population-based study[J]. J Clin Oncol, 2010,28(5):830-834. [3] Kuroki Y, Tsuchida K, Go I, et al. A study of innate immunity in patients with end-stage renal disease: special reference to toll-like receptor-2 and-4 expression in peripheral blood monocytes of hemodialysis patients[J]. Int J Mol Med, 2007,19(5):783-790. [4] Cecilie B, Ulf-Henrik M, Ola L, et al. Multiple myeloma and infections: a population-based study based on 9,610 multiple myeloma patients[C]//Blood (ASH Annual Meeting Abstracts), 2012,120: 945. [5] Pagano L,Girmenia C, Mele L, et al. Infections caused by filamentous fungi in patients with heamatologic malignancies. A report of 391 cases by GIMEMA infection program[J]. Heamatologica, 2001, 86(8): 862-870. [6] Pagano L, Caria M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study[J]. Haematologica, 2006,91(8):1068-1075. [7] 王彦艳,沈志祥.血液病真菌相关感染[J].国际输血及血液学杂志,2010,33(5):385-386. [8] Nencioni A, Schwarzenberg K, Brauer KM, et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation[J]. Blood, 2006,108(2):551-558. [9] Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial[J]. Lancet, 2006,367(9513): 825-831. [10] Kliemann DA, Pasqualotto AC, Falavigna M, et a1. Candida esophagitis: species distribution and risk factors for infection[J]. Rev Inst Med Trop Sao Paulo, 2008, 50(5): 261-263. [11] Weerasuriya N, Snape J. A study of candida esophagitis in elderly patients attending a district general hospital in the UK[J]. Dis Esophagus, 2006, 19, 189-192. [12] Nicholas K, John K, Lori M. Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome[J]. Antimicrob. Angent Chemother, 2005, 49(9). 3616-3623. [13] 黄蓓晖,李娟,刘俊茹.多发性骨髓瘤合并侵袭性真菌感染的临床特点及易感因素分析[J].中华内科杂志,2009,12(12):1026-1030. [14] 中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌感染的诊断标准与治疗原则(第三次修订)[J].中华内科杂志,2010,49(5):451-454. [15] 念珠菌病诊断与治疗:专家共识[J].中国感染与化疗杂志,2011,11(2):81-95. [16] Chen HF, Wu TQ, Li ZY, et al. Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance[J]. Onco Targets Ther, 2012,5:329-334. [17] Pappas PG, Kauffman CA, Andes D, et a1. Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 48(5): 503-535. |